APPLICATIONS PUBLISHED 19 JANUARY 2005
Published: 1-Feb-2006
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Prevention of myocardial infarction induced ventricular expansion and remodelling
Myomend 1496862*
Preparation and use of a stable formulation of allosteric effector compounds
Allos Therapeutics 1496863*
Pharmaceutical compsn containing lamotrigine particles of defined morphology
Teva Pharmaceutical Industries 1496864*
Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations
Schering 1496865*
Process for preparing tannate liquid and semi-solid dosage forms
Kiel Laboratories 1496866*
Drug-complex microparticles and methods of making/using same
Lavipharm Laboratories 1496867*
Controlled release pharmaceutical compsns of carbidopa and levodopa
Ranbaxy Laboratories 1496868*
Coated particles with prolonged release and tablets containing same
Ethypharm 1496869*
Dosage form and method for producing same
Roehm 1496870*
Polysaccharide capsules and methods of preparation
FMC Biopolymer 1496871*
Functional foods containing a phospholipid-containing stable matrix
Bioghurt Biogarde 1496872*
Chewable soft capsule
Banner Pharmacaps 1496873*
Transdermal patches having a siliconic adhesive matrix stabilised with methacrylic copolymers
FT Holding 1496874*
Use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix
Ökopharm Forschungs- und Entwicklungs 1496875*
Aerosol formulation for inhalation comprising a tiotropium salt
Boehringer Ingelheim Pharma 1496876*
Method and compsn for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
Novo Nordisk 1496877*
Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
Celgene 1496878*
Regulation of a novel colon specific retinol dehydrogenase by APC and CDX2
The University of Utah Research Foundation 1496879*
Synergistic effects of nuclear transcription factor NF-KB inhibitors and anti-neoplastic agents
Research Development Foundation 1496880*
Chromium compsns and methods for using the same for inhibiting drug-induced insulin resistance
Nutrition 1496881*
Tolterodine salts
Pharmacia & Upjohn 1496882*
Method for treating ileus with an alpha-ketoalkanoic acid, ester or amide
Critical Therapeutics 1496883*
Association of an antithrombotic agent with aspirin and use thereof for treating atherothrombotic diseases
Les Laboratoires Servier 1496884*
Use of conjugated linoleic acid derivatives
Loders Croklaan 1496885*
Non-toxic amounts of protein-aggregating substances stimulate HSP70 expression and function as anti-tumour agents
multimmune 1496888*
Stabilised ascorbic acid derivatives
Showa Denko 1496889*
Substituted beta-aminoalcohols used as medicaments
Gruenenthal 1496890*
Methods for modulating phototoxicity
University of Arizona 1496891*
1H-benzo(F)indazol-5-yl derivatives as selective glucocorticoid receptor modulators
Merck 1496892*
Neuroprotectant methods, compsns, and screening methods thereof
Oxis International 1496893*
Angiogenesis inhibitors
Carlsbad Technology 1496894*
Use of cyclopamine in the treatment of psoriasis and other skin disorders
Tas, Sinan 1496895*
Inhibitors of AKT activity
Merck 1496896*
Tyrosine kinase inhibitors
Merck 1496897*
Tyrosine kinase inhibitors
Merck 1496898*
Use of materials having zinc ionophoric behaviour
Procter & Gamble; Arc Chemicals 1496899*
New pharmaceutical compsns based on anticholinergics and P38 kinase inhibitors
Boehringer Ingelheim Pharma 1496900*
Compsns comprising MMP7 modulators for the treatment of chronic pain
Novartis 1496901*
Medicaments containing steroids and a novel anticholinesterase drug
Boehringer Ingelheim 1496902*
Anhydrovinblastine for treatment of cancer
Access Oncology 1496903*
Pharmaceutical containing N, N'-disubstituted piperazine compounds
Gruenenthal 1496904*
Modulators of hedgehog signaling pathways, compsns and uses related thereto
Johns Hopkins University School of Medicine 1496905*
Inhibitors of AKT activity
Merck 1496906*
Tyrosine kinase inhibitors
Merck 1496907*
Combination of glivec(STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
Virginia Commonwealth University; The Government of the United States of America, as represented by The Department of Veterans Affairs 1496908*
Combination therapy for the treatment of cancer
AstraZeneca 1496909*
Kinase inhibitors
Abbott Laboratories 1496910*
Use of A2A adenosine receptor agonists for the treatment of inflammatory diseases
University of Virginia Patent Foundation 1496911*
Combination of brimonidine and timolol for topical ophthalmic use
Allergan 1496912*
Neuroprotective spirostenol pharmaceutical compsns
Samaritan Pharmaceuticals; Georgetown University 1496913*
(20s)-alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor vitamin D3 and their uses
Wisconsin Alumni Research Foundation 1496914*
Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
Brain'n'Beyond Biotech 1496915*
Metastasis modulating activity of highly sulphated oligosaccharides
Greenville Hospital System 1496916*
Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment of immunomodulatory disorders
Astion Development 1496918*
Pharmaceutical compsn comprising arsenite for the treatment of malignancy
Korea Microbiological Laboratories 1496918*
Immobilisation and stabilisation of virus
The University of Strathclyde 1496919*
Pharmaceutical compsn containing an extract from Barleria prionitis linn and its process of preparation
Council of Scientific and Industrial Research 1496920*
Preparation containing a mixture of picrorrhiza and ginkgo for the relief of disease
Larkins, Nicholas 1496921*
Nutritional supplement and method of delivery
Mann, Douglas 1496922*
Cancer immunotherapy
The Penn State Research Foundation 1496923*
Treatment of gastroparesis
Eli Lilly 1496924*
Use of interleukin-24 to treat ovarian cancer
ZymoGenetics 1496925*
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
Amgen 1496926*
Targeted immunogens
Aventis Pasteur; Aventis Pharmaceuticals 1496927*
Serum biomarkers in hepatocellular carcinoma
Ciphergen Biosystems; The Chinese University of Hong Kong 1496928*
Use of a C5A receptor antagonist in the treatment of fibrosis
Promics 1496929*
G-type peptides to ameliorate atherosclerosis
The Regents of the University of California 1496930*
Methods for treating an autoimmune disease using soluble CTLA4 molecule and a DMARD or NSAID
Bristol-Myers Squibb 1496931*
Anti-HIV compsn, production method thereof and medicament
Commissariat àl'Energie Atomique; Centre National de la Recherche Scientifique 1496932*
Use of interleukin-19 to treat ovarian cancer
ZymoGenetics 1496933*
Adjuvant enhanced immunotherapy
Endocyte 1496934*
Insulin and IGF-1 receptor agonists and antagonists
Novo Nordisk; DGI BioTechnologies 1496935*
Intraventricular haemorrhage thrombolysis
The Johns Hopkins University 1496936*
DNA vaccine combined with an inducer of tumour cell apoptosis
Institut National de la Sante et de la Recherche Medicale; University of Wales College of Medicine 1496937*
Particle-bound human immunodeficiency virus envelope glycoproteins and related compsns and methods
Progenics Pharmaceuticals 1496938*
Modified CEA nucleic acid and expression vectors
Aventis Pasteur 1496939*
Methods of inhibiting diabetes using PDE 11A inhibitors
Bayer Pharmaceuticals 1496940*
Glycodendrimers having biological activity
Polyetherics 1496941*
Microparticles comprising carbohydrate beads covalently linked with allergen
Biomay Produktions- und Handels-Aktiengesellschaft 1496942*
Oligomeric compounds having modified phosphate groups
Isis Pharmaceuticals 1496943*
Improved RAAV expression systems for genetic modification of specific capsid proteins
University of Florida Research Foundation 1496944*
Mycoplasma polypeptides
Iowa State University Research Foundation 1496945*
Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution
Mallinckrodt 1496946*
Removal of adenine during a process of pathogen reducing blood and blood components
Gambro 1496947*
